CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31

CYTOKINETICS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$62.65+0.70 (+1.13%)

Close on Oct 19, 2026

Market cap: $8.28M
P/E (TTM): –
Dividend yield: –

CYTOKINETICS INC income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31	FY 2006 2006-12-31
Revenue	88	18	7.53	95	70	56	27	32	13	106	29	47	31	7.56	4.00	2.58	82	–	–	–
Research & Development	416	339	330	241	160	97	86	89	90	60	46	44	49	36	37	38	40	–	–	–
General & Administrative	284	215	174	178	97	53	40	31	36	28	20	17	15	12	14	14	16	–	–	–
Operating Expenses	700	555	504	419	257	150	126	120	127	88	66	62	65	–	–	–	–	–	–	–
Total Costs & Expenses	–	–	–	–	–	–	–	–	–	–	–	62	65	48	52	52	55	–	–	–
Operating Income	-612	-536	-496	-324	-186	-94	-99	-89	-113	19	-37	-15	-34	-40	-48	-50	26	–	–	–
Interest Expense	46	38	28	19	16	16	6.62	3.80	3.02	2.70	0.27	0	0	0.00	0.04	0.18	–	–	–	–
Interest & Investment Income	–	–	–	11	1.00	5.30	4.50	4.20	–	0.45	0.16	0.10	0.10	0.08	0.13	0.32	–	–	–	–
Other Non-Operating Income	48	52	28	11	0.33	5.33	4.54	4.19	2.60	0.46	0.17	0.11	0.18	0.09	0.10	0.17	-1.40	–	–	–
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	–	–	–	0	0	-0.06	1.19	–	-0.02	–	–	–
Gain (Loss) on Investments	–	–	-0.04	-0.11	0	0.57	0	0	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	0	0.07	0.02	0.02	0	0.08	0.00	0.00	0.01	0.04	–	–	–
Pretax Income	–	–	–	–	–	–	–	-106	-128	16	-38	-15	-34	-40	-48	-49	25	–	–	–
Income Tax Expense	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-0.18	0.15	–	–	–
Net Income incl. Noncontrolling Interests	-785	-590	-526	-389	-215	-127	-122	-106	-128	–	–	–	-34	-40	-48	-49	25	–	–	–
Net Income	-785	-590	-526	-389	-215	-127	-122	-106	-128	16	-38	-15	-34	-40	-48	-49	25	-56	-49	-57
Net Income to Common	–	–	–	–	–	–	–	–	–	–	–	-15	-34	-42	-51	-49	25	–	–	–
EPS (Basic)(per share)	-6.54	-5.26	-5.45	-4.33	-2.80	-1.97	-2.11	-1.95	-2.59	0.41	-0.97	-0.41	-1.24	-2.30	-4.30	-4.62	2.58	–	–	–
EPS (Diluted)(per share)	-6.54	-5.26	-5.45	-4.33	-2.80	-1.97	-2.11	-1.95	-2.59	0.39	-0.97	-0.41	-1.24	-2.30	-4.30	-4.62	2.52	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	0.12	0.11	0.10	0.09	0.08	0.06	0.06	0.05	49	40	39	36	27	18	12	11	9.57	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	0.12	0.11	0.10	0.09	0.08	0.06	0.06	0.05	49	43	39	36	27	18	12	11	9.66	–	–	–
EBITDA	-602	-527	-484	-318	-184	-92	-98	-88	-111	19	-37	-14	-33	-40	-47	-48	28	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -1046.1%
Net margin: -1321.1%
Return on equity, FY2025: 197.5%

Financial strength

Current ratio: 6.66
Debt to equity: -1.59
Debt to assets: 14.3%
Cash to current liabilities: 140.7%

Valuation

P/E ratio: –
Price to sales: 0.12
Price to book: –
Dividend yield: –